Switch theme
Sign up to access all valuation multiples
Prestige Biologics Co Ltd is a CDMO-dedicated company that provides solutions of development and manufacturing tasks throughout the stages from the research/development, engineering, clinical production, commercial production, clinical support, and IND & BLA filing of biopharmaceutical products. Its product candidate includes HD201 (Herceptin Biosimilar).
2015
n/a
LTM Revenue n/a
LTM EBITDA n/a
$268M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Prestige Biologics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Prestige Biologics achieved revenue of $1.5M and an EBITDA of -$4.3M.
Prestige Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Prestige Biologics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.2M | $1.5M | XXX | XXX | XXX |
| Gross Profit | $2K | $0.4M | XXX | XXX | XXX |
| Gross Margin | 0% | 24% | XXX | XXX | XXX |
| EBITDA | -$7.0M | -$4.3M | XXX | XXX | XXX |
| EBITDA Margin | -590% | -294% | XXX | XXX | XXX |
| Net Profit | -$33.9M | -$12.3M | XXX | XXX | XXX |
| Net Margin | -2873% | -829% | XXX | XXX | XXX |
| Net Debt | $70.3M | $78.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Prestige Biologics's stock price is KRW 4125 (or $3).
Prestige Biologics has current market cap of KRW 319B (or $218M), and EV of KRW 393B (or $268M).
See Prestige Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $268M | $218M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Prestige Biologics has market cap of $218M and EV of $268M.
Prestige Biologics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Prestige Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Prestige Biologics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $268M | XXX | XXX | XXX |
| EV/Revenue | 181.1x | XXX | XXX | XXX |
| EV/EBITDA | -61.6x | XXX | XXX | XXX |
| P/E | -10.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -23.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPrestige Biologics's NTM/LTM revenue growth is n/a
Prestige Biologics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Prestige Biologics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Prestige Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Prestige Biologics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -294% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -38% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 89% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 160% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 429% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1141% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Prestige Biologics acquired XXX companies to date.
Last acquisition by Prestige Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . Prestige Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Prestige Biologics founded? | Prestige Biologics was founded in 2015. |
| Where is Prestige Biologics headquartered? | Prestige Biologics is headquartered in South Korea. |
| Is Prestige Biologics publicy listed? | Yes, Prestige Biologics is a public company listed on KRX. |
| What is the stock symbol of Prestige Biologics? | Prestige Biologics trades under 334970 ticker. |
| When did Prestige Biologics go public? | Prestige Biologics went public in 2021. |
| Who are competitors of Prestige Biologics? | Similar companies to Prestige Biologics include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Prestige Biologics? | Prestige Biologics's current market cap is $218M |
| What is the current revenue growth of Prestige Biologics? | Prestige Biologics revenue growth between 2023 and 2024 was 25%. |
| Is Prestige Biologics profitable? | Yes, Prestige Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
